For any further information
Rexon-Eye field of application
The Rexon-Eye device currently finds its main application in the treatment of dry eye (DE), a complex pathology due to trauma, inflammation, deficit, infection, or other, which causes abnormalities of the ocular surface and eyelids, and in the composition of the tear film, with significant repercussions on vision.
Rexon-Eye, unique in the therapeutic device landscape, is successfully used in all DE patients, whether they are hyposecretive (“aqueous deficient”, ADDE), evaporative (EDE), or mixed.
The Rexon-Eye Difference
Compared to other devices on the market that often simply warm the treated area and are only able to alleviate symptoms of the disease, Rexon-Eye applies a treatment capable of stimulating recovery of normal function of the organs involved.
The hypothesis behind these benefits is that the QMR signal applied by the device stimulates the natural regeneration of the lacrimal system of patients, reactivating glandular tissue and physiological tear secretion, and thus providing functional benefits to the entire lacrimal functional unit.
Main clinical studies
Ophthalmology Clinic, Charité University Hospital, Berlin, Germany
In this first exploratory trial, 7 subjects were treated with evaporative or hyposecretive DE.
—
Six of them showed significant improvement in both the objective and subjective parameters that characterize dry eye.
Ophthalmology Clinic, University Hospital, Verona, Italy
26 subjects, with evaporative or hyposecretive DE, were treated and then examined up to one year from the end of the treatment.
—
An important aspect of this study is the confirmation of the long-term benefits of Rexon-Eye treatment: some of the measured parameters were still improving at the end of the one-year observation period. The results of the study are reported in a work published in the British Journal of Ophthalmology, to which reference may be made for further information.
Cornea and Ocular Surface Unit, San Raffaele Hospital Research and Care Institute, Milan
25 subjects, all affected by Evaporative DE (Meibomian Gland Disease, MGD), were treated with Rexon-Eye.
—
In this specific type of DE, it is important to evaluate the benefit obtained on the functionality of the Meibomian glands, which are responsible for generating the lipid substance that limits tear evaporation. The parameters measured to characterize this specific functionality, relating to the quantity and quality of the secretion, showed a significant improvement after treatment with Rexon-Eye.
—
The results of the study are reported in a work published in Cornea, to which reference may be made for further information.
Carones Vision (now ADVALIA Vision), Milan, Italy
9 subjects, affected by an advanced mixed form of DE (both evaporative and hyposecretive), were treated with Rexon-Eye.
—
In this particularly difficult to treat patient group, the measured parameters also showed significant improvement after treatment with Rexon-Eye.
—
The results of the study are reported in the ARVO 2020 congress proceedings, to which reference may be made for further information.
Department of Ophthalmology, Konstantopouleio General Hospital, Athens, Greece
18 subjects, affected by an advanced mixed form of DE (both evaporative and hyposecretive), were treated with Rexon-Eye.
—
In this study, particular attention was paid to evaluating the benefit offered by Rexon-Eye in the reduction of the inflammatory state, characteristic of DE. In this case as well, the measured parameters showed a significant improvement in the treated patients.
—
The results of the study are reported in the ARVO 2021 congress proceedings, to which reference may be made for further information.
